BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 11525567)

  • 1. Technology evaluation: IMC-1C11, ImClone Systems.
    Hunt S
    Curr Opin Mol Ther; 2001 Aug; 3(4):418-24. PubMed ID: 11525567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.
    Posey JA; Ng TC; Yang B; Khazaeli MB; Carpenter MD; Fox F; Needle M; Waksal H; LoBuglio AF
    Clin Cancer Res; 2003 Apr; 9(4):1323-32. PubMed ID: 12684400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis inhibition in solid tumors.
    Rosen LS
    Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
    Kunkel P; Ulbricht U; Bohlen P; Brockmann MA; Fillbrandt R; Stavrou D; Westphal M; Lamszus K
    Cancer Res; 2001 Sep; 61(18):6624-8. PubMed ID: 11559524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-angiogenesis targeting drugs: a review].
    Jia K; Li J
    Ai Zheng; 2008 Apr; 27(4):442-6. PubMed ID: 18423135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacia's SU5416 not effective.
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):5. PubMed ID: 12113066
    [No Abstract]   [Full Text] [Related]  

  • 10. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice.
    Kamiyama M; Ichikawa Y; Ishikawa T; Chishima T; Hasegawa S; Hamaguchi Y; Nagashima Y; Miyagi Y; Mitsuhashi M; Hyndman D; Hoffman RM; Ohki S; Shimada H
    Cancer Gene Ther; 2002 Feb; 9(2):197-201. PubMed ID: 11857038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
    Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of angiogenesis and clinical application of anti-angiogenesis].
    Takahashi Y; Mai M
    Nihon Geka Gakkai Zasshi; 2001 May; 102(5):381-4. PubMed ID: 11394000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
    Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of extracellular gene of VEGF receptor KDR on growth of human bladder carcinoma in nude rats].
    Zhang Z; Zeng G; Zhang Z
    Zhonghua Yi Xue Za Zhi; 2001 Jun; 81(11):684-6. PubMed ID: 11798950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
    Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation of angiogenesis with expression of vascular endothelial growth factor and its receptors in lung carcinoma].
    Zhang G; Zhao M; Xu M; Yang Y; Wang M; Yang C
    Zhonghua Jie He He Hu Xi Za Zhi; 2002 Feb; 25(2):89-93. PubMed ID: 11953105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.
    Bocci G; Man S; Green SK; Francia G; Ebos JM; du Manoir JM; Weinerman A; Emmenegger U; Ma L; Thorpe P; Davidoff A; Huber J; Hicklin DJ; Kerbel RS
    Cancer Res; 2004 Sep; 64(18):6616-25. PubMed ID: 15374976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
    Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB
    Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.